Abstract
Remdesivir is a novel nucleotide analogue antiviral drug with in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). Food and Drug Administration (FDA) and Drug Controller General of India have authorized the emergency use for the treatment of COVID-19 under an